Published Date: 04 Mar 2023
Karnataka: Karnataka Examination Authority (KEA) yog PG AYUSH ...
Read Full NewsBaseline RV Dysfunction May predict Sotatercept response in PAH
The FDA accepted uniQure's biologics license application for ifezuntirgene inilparvovec and granted it Priority Review, setting a target action date of May 1, 2027.
Pediatric epilepsy care goes beyond seizures, addressing mental health, learning needs, coordinated referrals, equitable access, and smoother transition to adult services.
Sabirnetug failed to meet its primary endpoint in Acumen Pharmaceuticals' phase 2 ALTITUDE-AD trial for early Alzheimer disease, prompting the company to end development.
AL-S Pharma outlined the design of AP101-03, a planned phase 3 trial of AP-101 in sporadic and SOD1-associated ALS, at the 2026 NEALS Annual Meeting.
Alnylam Pharmaceuticals reported initial Phase 1b findings showing brezosiran reduced cerebrospinal fluid mutant huntingtin levels by a mean of 60% to 64% at 3 months, with plans for a pivotal study in 2027.
The executive medical director at AbbVie discussed the FDA approval of tavapadon, the first D1/D5 dopamine agonist for Parkinson disease, including the supporting TEMPO trial data and safety considerations.
1.
Discovery of estrogen receptor 'switches' may aid breast cancer treatment
2.
Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers
3.
'Next Berlin Patient' Adds to Small but Growing Number of People Cured of HIV
4.
The clinical trial of ENZAMET shows promise as a treatment for prostate cancer.
5.
GLP-1 Drugs Linked to Lower Colorectal Cancer Risk for Diabetes Patients.
1.
Understanding QSOFA: A Vital Tool for Recognizing Sepsis
2.
Environmental Carcinogen Avoidance in Precision Prevention
3.
Tumor Evolution Dynamics and Clinical Prognosis
4.
Personalized Cancer Vaccines: The Next Frontier in Precision Oncology
5.
Strategic Directions in Oncology in the Digital Era
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
2.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion
3.
Blood Clotting Disorders Explained
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III
5.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation